Sequenom, Inc.(NASDAQ: SQNM) is currently trading at $4.34, 3.34% higher. Manufactures DNA detection and sequencing equipment. The Company's two business units combine to utilize their MassARRAY system, SNP assay portfolio, disease gene discovery programs and DNA sample repository. Sequenom provides genetic analysis products that translate genomic science into solutions for biomedical research, molecular medicine and agricultural applications.
Will SQNM Move Higher After Today’s Sudden Selling Activities? Don’t Miss The Free Trend Analysis here http://beststocksdaily.com/p2/index.php?company=SQNM
Arena Pharmaceuticals, Inc.(NASDAQ: ARNA) added 0.21% to $9.72. Arena Pharmaceuticals, Inc. (Arena) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors (GPCRs), in four therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. After completing various studies, analyses and other activities in response to the lorcaserin CRL, in December 2011, the Company resubmitted the lorcaserin NDA.
ArQule, Inc.(NASDAQ: ARQL) is lower 15.15% to $2.48. ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. It employs technologies, such as its ArQule Kinase Inhibitor Platform to design and develop drugs. Its product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase (c-Met). C-Met is a target for cancer therapy, based on its multiple roles in cancerous cell proliferation, tumor spread, new blood vessel formation and resistance to certain drug therapies.
Celgene Corporation(NASDAQ: CELG) among the losers and the stock fell 0.73% to $94.78. Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.
Gilead Sciences, Inc.(NASDAQ: GILD) is lower 0.29% to $77.71. Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific.
Beststocksdaily’s team is engaged in providing valuable and updated news information on U.S. stocks on a regular basis. Beststocksdaily’s instant stock news on Major Gainers, Hot Stocks and various other stocks, guides investors in making the wise stock market investments decision. To Get Instant updates in the inbox, readers are advised to sign up for free at Beststocksdaily.com.
The assembled information disseminated by beststocksdaily.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. beststocksdaily.com does expect that investors will buy and sell securities based on information assembled and presented in beststocksdaily.com. PLEASE always do your own due diligence, and consult your financial advisor.
1419 Westwood Blvd Los Angeles, CA